Pfizer Inc (PFE) FY2025Q4 Earning Prediction
Pfizer Inc (PFE) is set to release its FY2025Q4 earnings performance on 02/03 06:45:00 ET in Pre-Market trading. Consensus forecasts predict a revenue of 16.84B and an earnings per share (EPS) of 0.56 for the FY2025Q4. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
The company's earnings forecast suggests a neutral performance due to balanced risks and mixed results from its pipeline and cost structure.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Logic & Justification
Fact Data Analysis:
- Non-COVID Product Growth:
Vyndaqel’s Phase 3 BREAKWATER trial (64% efficacy in colorectal cancer) and HYMPAVZI’s hemophilia data (93% bleeding reduction) validate strong demand. However, these products are not yet major revenue drivers.
Licensing deals (Novavax’s Matrix-M adjuvant, Madrigal’s ervogastat) diversify pipelines but lack near-term revenue impact.
- Gross Margin Stability:
- Cost realignment ($ 7.2B savings by 2026) supports margin discipline, but upfront payments ($50M to Madrigal, $150M to Fosun) and R&D reinvestment offset near-term benefits.
- Operating Expenses:
- Adjusted R&D expenses ($ 10.5B–$ 11.5B) and SI&A ($ 12.5B–$ 13.5B) remain elevated due to obesity/oncology trials (15 studies in 2026), pressuring EPS.
- Abrysvo & Obesity Pipeline:
- GLP-1 candidate YP05002 (Phase 1) and GIPR antagonist PF-07976016 (Phase 2) position Pfizer for long-term obesity growth, but Phase 3 data is years away.
- Regulatory & Policy Risks:
- Trump’s drug pricing pressure and CDC’s revised vaccine guidelines create uncertainty, offset by U.S.-U.K. pricing agreement (25% NHS price hikes for new drugs).
Balanced Risks:
Positive Catalysts: Vyndaqel growth, cost savings, strategic collaborations.
Negative Catalysts: High R&D spend, COVID revenue decline ($5B guidance for 2026), policy risks.
Tactical Strategy Recommendations
Trading Strategy
- Options: Sell straddles (IV30 ~24% implies muted move).
- Stock: Avoid directional bets; wait for post-earnings dip if guidance disappoints.
- Pairs Trade: Long PFE (value) vs. Short NVO/LLY (overvalued obesity peers).
Rationale: Mixed Fact Data and high expectations (5.45% stock outperformance) limit upside. Neutral reflects balanced risks, but EPS likely misses on costs.
Earnings Surprise Analysis
PFE Transcript
The earnings call summary indicates strong financial metrics with raised EPS guidance, significant cost savings initiatives, and ongoing product development in high-potential areas like lung cancer. Despite lower COVID-19 product performance, non-COVID products are doing well. The Q&A session revealed optimism about product pipelines and strategic AI investments. While some details were deferred, the overall sentiment is positive due to promising R&D advancements and strategic initiatives. The lack of specific market cap data limits precise impact prediction, but the positive aspects outweigh negatives, suggesting a positive stock reaction.
The earnings call shows strong revenue growth and a solid cash position, with a positive outlook on lithium pricing and strategic diversification through the Tungsten acquisition. The share buyback program and lack of debt further strengthen the financial health. Despite some uncertainties in shipment timing and royalty transaction timelines, the company's focus on high-return projects and stable long-term lithium demand support a positive sentiment.
PFE Slides
PFE Report
Frequently Asked Questions
What is the Pfizer Inc FY2025Q4 Earnings Release Date and Time?
Pfizer Inc (PFE) is scheduled to release its FY2025Q4 earnings report onFeb 3, 2026, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Pfizer Inc FY2025Q4 Revenue and EPS?
Analysts' consensus predicts 16.84B in revenue and an EPS of 0.56 for Pfizer Inc's FY2025Q4.
What Does Intellectia's AI Predict for Pfizer Inc FY2025Q4 Earnings?
Intellectia's exclusive AI algorithms forecast a Neutral forPfizer Inc's FY2025Q4 earnings, with a prediction date of Feb 3, 2026. Pfizer Inc The company's earnings forecast suggests a neutral performance due to balanced risks and mixed results from its pipeline and cost structure.
How Can I Use This Earnings Prediction to Trade PFE Stock?
Leverage Intellectia's AI forecast to position trades ahead of theFeb 3, 2026 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Pfizer Inc FY2025Q4?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
